Our objective was to investigate the presence of a B and T cell immune response directed against the glycine-rich cell wall protein (GRP) in patients with different autoimmune disorders and with food allergy. GRP is an ubiquitous food protein that has high homology with cytokeratins and other self proteins [Epstein-Barr virus nuclear antigen-1 (EBNA-I), heterogeneous nuclear ribonucleoprotein, fibrillar collagen] which are common targets in autoimmune disorders. A peptide (GGYGDGGAHGGGYGG) derived from GRP was used to screen human sera in direct and competitive ELISA assay. Anti-GRP-specific IgG were analyzed for their ability to cross-react with autoantigens. The intracellular cytokine profiles of the peptide-specific T cell clones obtained from representative patients have been studied. BALB/c mice were immunized with the peptide coupled to the carrier protein keyhole limpet hemocyanin (KLH). Serum IgG antibodies directed against the GRP peptide were detected in several autoimmune disorders and in food allergic patients, and were able to cross-react with autoantigens including keratin, collagen and EBNA-I. Twenty-five T cell clones showed a specific proliferative response to the GRP peptide and were of the T h 0 phenotype. Eight of the 10 BALB/c mice immunized with the peptide coupled to KLH developed an autoimmune response. Our data suggest that phylogenetically highly conserved epitopes in plants, viruses and humans may be responsible for an autoimmune response in susceptible individuals. They also indicate that the antigen spreading of a particular sequence among apparently divergent proteins may participate to initiate or amplify an immune response.
Introduction
The extensive search for pathogenetically relevant autoperpetuating process of organ inflammation and destruction (2), and (iv) the timing of MHC up-regulation in the target antigen targets in autoimmune diseases has been disappointing so far. Different reasons may account for this difficulty:
organ might be able to trigger the beginning of the process (3). Attempts to characterize autoantigenic epitopes in different (i) different autoantigenic epitopes may be important for each patient depending on the MHC background, (ii) the set of autoimmune diseases have been made possible using random peptide phage libraries which allow the identification of the encountered foreign antigens may select and activate particular cross-reacting autoreactive T cells (1) , (iii) the local ligands for disease-specific antibodies whether the antigen is known or not (4-7). This approach identifies linear, coninflammation can induce the release of additional self-antigens and/or epitope spreading which leads to a chronic selfformational as well as mimic epitopes, and it has been used
The first two authors contributed equally to this work of several autoimmune disorders and in food allergy. The GRP peptide was able to elicit a specific T cell response:
GGYGDGGAHGGGYGG peripheral mononuclear cells (PBMC) derived from patients :: : ** :: * ** * with different diseases proliferated to the peptide and antigenProcollagen α1 (V) (327-345) ANYDTYGGGRRGKGYKGRA specific T cell clones could be generated from such patients.
GGYGDGGAHGGGYGG
These data suggest that (auto)immune responses can be Rheumatology (22, 23) . Psoriatic arthritis (PsA) was diagnosed by the presence of psoriasis and a seronegative peripheral arthritis, with or without axial skeletal involvement. Chronic idiopatic urticaria (CIU) was characterized by recurrent episodes of diffuse erythematous wheals with severe pruritus to screen Ig fractions obtained from patients with multiple sclerosis (8), chronic immune thrombocytopenic purpura (9), lasting for Ͼ6 weeks. Food allergy was identified by the presence of specific IgE and positive double-blind placebotype 1 diabetes mellitus (10), systemic lupus erythematosus (SLE) (11) and rheumatoid arthritis (RA) (12-14). One of the controlled challenge test; the offending foods were cereals, fruits and vegetables in 20 of 29 patients, fish in five of 29 selected peptides identified by Ig from RA patients (12) showed homology with cereal glycine-rich cell wall proteins and diary products in four of 29 patients. Aeroallergy was assessed by a history of seasonal or perennial rhinitis and/or (GRP) and with the Epstein-Barr virus nuclear (EBV) antigen-I (EBNA-I). Analysis of GRP 1.8 (15), a ubiquitous protein found asthma and positive skin test for pollens or house dust mite. The patients with chronic parvovirus B19 infection (CPI) are in French bean and related species, shows the presence of Gly-Ala repeated sequences homologous to EBNA-I and described in details elsewhere (24) . The number of the patients studied is reported in Table 2 . cytokeratins. Many studies have shown the ability of anti-EBNA-I antibodies to cross-react with different autoantigens
The HLA status of patients with CPI has already been reported (24) . In patients with PsA HLA DR4, DR1 and DR7 such as heterogeneous nuclear ribonucleoprotein (hnRNP) (16), cytokeratin, collagen and actin in RA (17,18); the crosswere found in three patients each; DR3, which is associated with a more aggressive form of the disease and the presence reactions can be inhibited with synthetic peptides containing the Gly-Ala repeat sequence, implying that the cross-reactivity of erosive arthritis, was present in two patients. We did not find particular HLA class II antigens more frequently present is due to anti-Gly-Ala antibodies that recognize both the host proteins and the EBNA-I repeat. A 15 amino acid synthetic in patients with SLE, CIU and food allergy, whereas in RA there was an increased prevalence of DR4 (30% of patients peptide corresponding to amino acids 436-454 of GRP 1.8 and sharing homology with EBNA-I, fibrillar collagen and versus 15% of controls; P ϭ 0.008). When the DR4 and DR1 where analysed at molecular level no difference was found procollagen (Table 1) has been shown to induce humoral (14) and T cell responses in RA (19). Taken together, these data in DR4 suballeles (*0401, *0402, *0403, *0404, *0405, *0408) between patients and controls; as far as DR1 suballeles suggest that the autoimmune response in RA but also in other autoimmune diseases may not be as heterogeneous as were concerned (*0101, *0102, *0103) there was a statistical difference in the frequency of *0102 between the two groups originally thought. A possible consequence of such hypothesis is that the identification of widespread (auto)antigens may (46% of patients versus 19% of controls; P ϭ 0.008). IgM rheumatoid factor was present in 25 of 32 RA allow their use in the suppression of autoimmunity by oral administration. The suppression of autoimmunity by oral antipatients and its level varied between 105 and 770 IU/ml (n.v. Ͻ 60 IU/ml). gen administration may be a feasible therapeutic option (reviewed in 20) and the induction of oral tolerance can be a All the patients' sera were tested for the presence of the following autoantibodies: anti-ssDNA antibodies, anti-keratin therapeutic strategy also in food allergy (reviewed in 21). Based on the observation that Gly-Ala repeated sequences antibodies, anti-collagen II antibodies, anti-RNP antibodies. Anti-ssDNA antibodies were present in 37 of 37 SLE patients are present in food proteins as well as in viruses and selfproteins, we decided to investigate the presence of antiand in two of 32 RA patients, anti-keratin antibodies in seven of 32 RA patients and two in 12 of PsA patients, anti-collagen GRP antibodies in a large panel of sera from patients with sera diluted 1: 100 from normal age-and sex-matched mAb and reagents subjects were used as control group. Optical density values higher than the mean ϩ 3 SD of each serum dilution of the The purified mAb anti-CD56 (Leu19, IgG1), anti-CD8 (Leu2a, IgG1), anti-CD4 (Leu3a, IgG1), anti-CD3 (Leu4, IgG1) and control group (OD Ͼ 70 for the GRP peptide and OD Ͼ 85 for the recombinant protein) were considered positive. anti-CD19 (Leu12, IgG1) were from Becton Dickinson (San Jose, CA). The purified mAb anti-CD16 (KD1, IgG2a) was a
The direct and competitive ELISA for human keratin, collagen type II and actin has been described (24) . The kind gift of Professor L. Moretta (Genoa, Italy). The class II specific mAb DC1-12 was a kind gift of Professor R. Accolla ELISA assay for EBNA-I was performed using a commercially available kit (Sigma). (Genoa, Italy). Phycoerythrin (PE)-or FITC-conjugated goat anti-mouse antisera were from Southern Biotechnology
Immunization of BALB/c mice Associates (Birmingham, AL). Human keratin, collagen type II and actin were purchased from Sigma (St Louis, MO).
The synthetic peptide was coupled to the carrier protein keyhole limpet hemocyanin (KLH) and emulsified in Freund's Affinity purification of IgG anti-peptide and anti-keratin antiadjuvant. Mice were injected 5 times (the first time in bodies complete Freund's adjuvant, the other times in incomplete adjuvant) at the base of the tail at 15 day intervals. The Serum IgG was obtained by affinity purification using a Protein A-Sepharose column (Pharmacia, Uppsala, Sweden). The animals were bled 7 days after the last injection and the sera tested in ELISA. Control animals were injected with adjuvant synthetic peptides or human keratin (5 mg antigen/g dried Sepharose powder) were coupled to Sepharose CL4B (Pharalone, keyhole limpet hemocyanin (KLH) alone or coupled with the irrelevant peptide. macia), according to the manufacturer's instructions. Affinitypurified IgG samples diluted in PBS were applied to the Generation of CD4 ϩ -specific T cells clones and flow column. Bound IgG was eluted with 0.1 M glycine (pH 2.5) cytofluorimetric analysis and dialyzed against PBS.
PBMC derived from patients were isolated on Ficoll-Hypaque ELISA assay gradient and cells were then incubated with peptide at 20 µg/ml in 96 U-bottomed microplates in complete medium. The synthetic peptides and the recombinant proteins were used at a concentration of 20 µg/ml in PBS to coat polystyrene After 10 days of culture in absence of rIL-2 the cells were incubated with a mixture of anti-CD16 (KD1), anti-CD56 plates (Nunc, Roskilde, Denmark). After blocking with 5% dry non-fat milk in PBS, the antibodies diluted in 2.5% dry non-(Leu19) and anti-CD8 (Leu2a) mAb and purified by immunodepletion using goat anti-mouse Ig coated with magnetic fat milk and 0.05% Tween in PBS were added and incubated beads (Unipath, Milan, Italy) (26) . Viable cells were cloned Table 2 shows the results of the ELISA assay performed in the patients studied: the frequency of patients' sera able to under limiting dilution in the presence of irradiated peripheral blood lymphocytes as feeder cells in complete medium and recognize the GRP peptide was particularly high in certain diseases such as PsA, CIU and SLE. A large number (15 of of exogenous rIL-2 (Cetus, Emeryville, CA) as described for T cell cloning (27) . 29) of sera from patients with food allergy also reacted with the peptide; on the contrary, none of the 21 patients with Cells were stained with the appropriate mAb followed by fluoresceinated goat anti-mouse Ig (28); control aliquots were aeroallergy and of normal donors recognized the peptide. The results were confirmed in each patient's serum by competitive stained with the fluoresceinated reagent alone. All samples were analyzed on a flow cytometer FACSort (Becton immunoassays where the peptide in liquid-phase competition experiments was shown to be able to displace the binding of Dickinson) gated to exclude non-viable T cells.
serum IgG from the peptide on the solid phase (Fig. 1A) .
Human mAb
Anti-GRP IgA antibodies were detected in two of 32 RA patients, in four of 37 SLE patients, in none of seven CPI Epstein-Barr virus-transformed cell lines were derived from patients, in one of 12 PsA patients, in three of 12 CIU selected individuals according to standard procedures (29) patients and in 11 of 29 food allergy patients. and were cloned in soft agar; the resulting Ig-producing Anti-GRP IgE antibodies were not detected in any clones were tested for antigen-binding activity by ELISA assay.
patients' group.
Proliferation assay
These data suggest that anti-GRP peptide IgG antibodies are widely present in the serum of patients with autoimmune PBMC or highly purified CD4 ϩ clones were cultured for 3 disorders and with food allergy. days in complete medium in 96-well U-bottom microplates (5ϫ10 5 cells/well) with irradiated autologous PBMC or B-EBVSerum anti-peptide antibodies specifically recognize the transformed cell lines (5ϫ10 5 cells/well). The following stimuli native recombinant protein were used: GRP peptide (20 µg/ml), an irrelevant peptide Prokaryotic expression plasmids encoding truncated forms (20 µg/ml) and rIL-2 (20 U/ml) as positive control. Cells were of the GRP were expressed in E. coli (15 confirm the reactivity of the sera with the peptide. Fifteen patients' sera containing serum antibodies against the GRP The T h subsets of the clones obtained was analyzed by flow peptide as well as normal controls' sera were tested on the cytometric assessment of intracytoplasmic cytokine content various forms of recombinant proteins. All the 15 sera reacted (reviewed in 30). Cells were stimulated with 25 ng/ml phorbol with the recombinant protein (GST1fGRPC) containing the 12-myristate 13-acetate (Sigma) plus 1 µg/ml ionomycin insert corresponding to the GRP peptide sequence, but not (Sigma) for 4 h in the presence of 10 µg/ml Brefeldin A with the other truncated versions of the molecule. Similarly (Sigma) (31) and were subsequently fixed with PBS containing sera which did not recognize the GRP peptide did not react 4% (v/v) paraformaldehyde and permeabilized in PBS/saponin with the recombinant protein. Normal human sera did not buffer (Sigma). Directly conjugated monoclonal anti-cytokine recognize the recombinant protein (data not shown). In a antibodies specific for IL-2, IFN-γ, 1L-4, IL-5 and IL-10 were competitive immunoassay the liquid-phase GRP peptide used to identify the cytokines produced [FITC-conjugated anticould displace the binding of serum Ig from the recombinant IFN-γ and R-PE-conjugated anti-IL-2 and -IL-4, from Becton protein on the solid phase (Fig. 1B) , further confirming the Dickinson; R-PE-anti-IL-5 and -IL-10, from PharMingen (San specificity of such antibody interaction. The data obtained Diego, CA)]. Specificity controls were performed using isoindicate that serum antibodies are able to recognize the GRP typical mAb (IgG2a-FITC and IgG1-R-PE, both from Becton peptide sequence even in the context of a larger molecule Dickinson). At least 30,000 events were acquired by FACScan such as the GRP recombinant protein. This observation is flow cytometer equipped with an argon ion laser (488 nm) important because it may constitute the basis for a wide crossand CellQuest software (Becton Dickinson).
reactivity of antibodies directed against the GRP peptide.
Serum anti-peptide antibodies cross-react with other auto-

Results
antigens Patients' sera recognize the synthetic peptide.
To further characterize the fine specificity of the binding of serum anti-GRP peptide antibodies we isolated the IgG anti-A peptide immunoselected from a phage display library using a pool of Ig from RA patients showed interesting homologies peptide component from the sera of five different patients by affinity chromatography using a peptide-Sepharose column. with a food-derived antigen, viral-encoded proteins and autoantigens (Table 1 ) (19). Based on the high homology Anti-GRP peptide antibodies affinity purified from five normal donors were used as control. Anti-GRP peptide antibodies between the peptide derived from GRP and common autoantigen targets we synthesized and used the GRP peptide to isolated from the patients' sera recognized the peptide in both direct and competitive ELISA, and they also reacted screen a large number of patients' sera affected by either autoimmune or allergic diseases as well as normal donors.
with the recombinant protein (data not shown). cross-react with autoantigens including keratin, collagen and EBNA-I. This cross-reactivity is not shown by anti-control peptide antibodies obtained from the same subjects. In a separate set of experiments anti-keratin antibodies These antibody preparations were then tested for their were affinity purified from the serum of patients GC and SP ability to recognize other autoantigens such as human keratin, using a keratin-Sepharose column. The purified antibody collagen type II, actin, EBNA-I. As shown in Table 3 , the antipreparations recognized human keratin in direct and competit-GRP peptide reacted with different autoantigens and the ive ELISA (data not shown). Such anti-keratin antibody populaaffinity of the interaction varied within the different serum tions were used to perform a cross-inhibition experiments in samples. On the contrary anti-GRP peptide antibodies purified which the binding of these antibodies to solid-phase keratin from the serum of normal subjects showed a low-affinity is competed by keratin and GRP peptide. As shown in Fig.  interaction with the GRP peptide and did not cross-react with 2(C and D), the binding of these antibodies to keratin is any of the autoantigens tested. Moreover 20 times more completely inhibited by keratin and only partially by GRP serum was needed to purify the same amount of anti-peptide Ig when compared to the patients' sera, indicating that such peptide. These data indicate that anti-GRP antibodies are able to cross-react with autoantigens (keratin, actin, EBNArecognize keratin, actin and EBNA-I. An example of this behavior is given in Fig. 3 . These results confirm at the clonal I), whereas not all the antibodies directed against such autoantigens are able to recognize the GRP sequence.
level our previous observations that anti-GRP antibodies produced in subjects with autoimmune disorders are able to These results indicate that the peptide studied identifies a shared epitope widely expressed in different diseases and cross-react with several autoantigens and this cross-reactivity may be relevant in the pathogenesis of the disease. that antibodies against such peptide recognize different autoantigen targets.
Normal mice immunized with the GRP peptide develop an autoimmune response EBV-transformed cell clones producing anti-GRP antibodies
Six EBV-transformed cell clones obtained from patients PG,
To further substantiate the role of the GRP peptide in inducing an autoimmune response, 10 BALB/c mice were immunized GC and SP produced anti-GRP peptide antibodies able to with the GRP peptide coupled to the carrier protein KLH. SLE (patients LoM, PG, ZP), PsA (patients LM and SP), RA (patients VM and GC) and CPI (patients BS, CoL, SE). PBMC Eight mice developed an anti-GRP peptide IgG and IgM response (Table 4) . Autoantibody activity against keratin, isolated from these patients were able to proliferate to the GRP peptide, but not to a control irrelevant peptide, whereas collagen II and EBNA-I was detected in all the mice which developed a strong anti-GRP response, and anti-peptide normal subjects did not show any proliferative response to the GRP peptide (data not shown). antibodies affinity purified from the pooled sera of five individual mice recognized the autoantigens as well (data not One hundred and fifty antigen-specific T cell clones were derived from the PBMC of the 11 patients studied. The clonal shown). On the contrary, autoantibody activity could not be detected in the sera of the animals injected with an irrelevant efficiency of the clonal procedures was 4.82% (SD Ϯ 1.1).
We then chose to characterize 38 clones on the basis of their peptide coupled to KLH, KLH alone or PBS alone. These data further indicate that the GRP peptide is able to induce an growth capability; all the clones proved to be CD4 ϩ by FACS analysis. The antigen specificity of the 38 clones was then autoimmune response through the production of anti-peptide antibodies cross-reacting with autoantigens. evaluated using the GRP peptide and EBV-transformed autologous B lymphocytes or autologous PBMC as antigenGeneration of peptide-specific T cell clones presenting cells. Twenty-five T cell clones showed a specific proliferative response to the GRP peptide, but not to an To evaluate the T cell response to the GRP peptide, 11 patients affected by different diseases were selected on the irrelevant control peptide. Of the 25 peptide-specific T cell clones, six were derived from patient SP, four from patient basis of a high anti-peptide serum IgG antibody titer. The 11 patients selected for the preparation of T cell clones were CA, two from patients SE, CG, VM, LM, PG, LoM, one from each of ZP, CoL, BS. The specificity of the proliferative affected by the following diseases: food allergy (patient CA), . Statistical analysis of the data was performed using the paired t-test; the differences between the proliferative responses of T cell clones to the GRP peptide and to the control peptide were statistically significant (P Ͻ 0.001).
response of the CD4 ϩ T cell clones obtained from the patients response against the GRP peptide can be elicited in patients affected by different autoimmune diseases. studied was confirmed by the following lines of evidence: (i) all the anti-GRP T cell clones did not proliferate in the presence Intracytoplasmic cytokine profile of the T cell clones studied of the GRP peptide when heterologous irradiated EBV cells or heterologous PBMC were used as antigen-presenting cells
In order to evaluate the T h subset of the peptide-specific T and (ii) preincubation of the CD4 ϩ anti-GRP peptide clones cell clones, we performed intracellular cytokine staining by FACS analysis. The 18 clones analyzed did not show a T h 1 with the class II-specific mAb D1-12 abolished the proliferative or T h 2 cytokine profile, since IFN-γ, IL-2 and IL-4 were response of these clones to the GRP peptide (data not simultaneously present (data not shown). These data suggest shown). Figure 4 shows the proliferative response of represthat GRP peptide-specific T cell clones belong to the T h 0 entative clones derived from different patients.
subset. PBMC obtained from two normal subjects were stimulated with the GRP peptide and subsequently cloned with the previously described procedure: differently from what was Discussion observed with the clones derived from the patients' PBMC, the CD4 ϩ T cell clones obtained from the two normal subjects This study shows that a peptide from a food-derived glycinefailed to proliferate to the GRP peptide (data not shown), rich cell wall protein is able to elicit a B and T cell immune further confirming the specificity of the anti-GRP T cell response in several autoimmune diseases. Such peptide has response observed in the group of patients examined.
a high homology with EBNA-I, cytokeratins, and other self antigens such as hnRNP, fibrillar collagen and procollagen Taken together, these results suggest that a specific T cell (19). Interestingly the reactivity to this peptide is not limited peptide is able to induce proliferation of PBMC isolated from patients with different diseases, whereas normal subjects do to a particular disease condition since anti-peptide IgG antibodies and peptide-specific T cell clones can be found in not proliferate to the peptide. To further analyze the T cell response to the peptide, a several autoimmune disorders and in food allergy, whereas normal subjects do not have detectable serum antibodies panel of CD4 ϩ peptide-specific T cell clones was derived from PBMC of patients with different disease conditions. CD4 ϩ directed against the peptide and their PBMC fail to proliferate to the peptide. The anti-GRP peptide antibodies purified from T cell clones specific for the GRP peptide could not be derived from the PBMC of normal healthy donors. Peptidethe sera of the patients studied were able to specifically recognize EBNA-I and different autoantigen targets (keratin, specific CD4 ϩ T cell clones may either be the consequence of a previous activation and expansion by exogenous anticollagen, actin), whereas such autoantigen binding activity was not displayed by the anti-control peptide antibodies gens, e.g. in the gut mucosa or more likely derive from normally present autoreactive T cell subsets (3). Independently from affinity purified from the same patients' sera and by the anti-GRP peptide antibodies eluted from the sera of healthy the mechanism involved in the generation of such CD4 ϩ T cell clones, these cells may be able to provide a T cell help donors. In the latter case the eluted antibodies showed a lowaffinity interaction with the peptide and did not recognize any to B cells for the generation of an IgG response towards the peptide, which will result in the production of large amounts of the autoantigens tested. The autoantigen binding profile of the anti-GRP peptide antibodies is similar to the one observed of cross-reacting anti-peptide antibodies. The presence of the same structural motif in the different autoantigens may with serum antibodies directed against P62, a synthetic peptide corresponding to the Gly-Ala repeat sequence of account for the promiscuity of such autoantibody response which seems to be a common feature of the immune response EBNA-I (18). In both cases affinity purified anti-peptide antibodies cross-reacted with the same autoantigens: keratin, in different autoimmune disorders. These results suggest that the immune response in autoimmune diseases may not be actin and collagen. The similar behavior of the two antipeptide antibody populations (anti-P62 and anti-GRP peptide)
as heterogeneous as originally thought. In this regard it is possible to view the autoimmune response as an oligoclonal can be ascribed to the presence of the common sequence Gly-Gly-Ala, which suggests that anti-Gly-Ala antibodies may expansion of a rather limited number of T cell subsets which share the capability of responding to a particular amino acid be responsible for the cross-reactions observed. An increased level of anti-Gly-Ala antibodies may account for the crosssequence. The process may result in the stimulation of cells able to deliver T cell help to a great number of B cell clones. reaction with structural endogenous proteins such as cytokeratins and collagen. In this regard, recent data obtained Thus, a large number of antibodies specific for different autoantigenic targets may arise as a response to a relatively in our laboratory using recombinant peptide libraries show that the Gly-Gly-Ala motif is recognized at high frequency in small number of amino acid sequences, probably due to a mechanism of molecular mimicry. randomly generated dodecamer peptides by autoantibodies belonging to different autoimmune diseases. This finding Interestingly, a B and T cell response to the GRP peptide can also be found in patients with food allergy. The absence further demonstrates an important role for this amino acid sequence as an antigen target in different diseases (Lunardi of anti-GRP-specific IgE antibodies in patients with food allergy suggests the possibility of a non-IgE-mediated immune et al., manuscript in preparation).
The finding that anti-GRP IgG antibodies are present at response to particular food-derived antigens which can be able either to block or to mediate histamine release from high frequency in the sera of autoimmune and food allergic individuals was further confirmed by the generation of human basophils and mast cells. The type of immune response elicited may be determined mAb from EBV-transformed lymphocytes belonging to representative patients. The anti-GRP peptide reactivity was present by the genetic background: the TCR-peptide-MHC interaction can control the direction of the functional immune at high frequency in a panel of randomly selected EBV clones. Similarly to the serum counterpart, these antibodies were able response, and MHC linkage to polarized T h 1-type and T h 2-type immune responses has now been reported for several to cross-react with several autoantigens. These results again support an important role for the GRP sequence in priming antigens and peptides (32) (33) (34) (35) (36) (37) (38) . The analysis of some of our peptide-specific T cell clones derived from peripheral blood an autoimmune response. This hypothesis was further substantiated by experiments in which the 15 amino acid GRP of patients with different diseases revealed a predominant T h 0 phenotype. We can hypothesize either that the GRP peptide was coupled to a carrier protein and its ability to elicit an autoimmune response in normal animals (BALB/c peptide is unable to induce a dominant T h 1 or T h 2 cytokine response, or that this peptide-specific CD4 ϩ subset found in mice) was analyzed. Interestingly mice displaying a strong anti-peptide response produced antibodies able to bind the the peripheral blood may switch to a T h 1 or T h 2 cytokine response at sites of autoimmune inflammation. GRP peptide, and to cross-react with several autoantigens including keratin, collagen II and EBNA-I.
Several lines of evidence suggest that the induction of oral tolerance by orally administered antigens has potential In accordance to the humoral response, T cell responses can be elicited by the GRP peptide in different patients and therapeutic applications for the treatment of autoimmmune and food-allergic diseases (20, 21) . In this regard the finding in several disease conditions. A T cell response against the GRP peptide has been already described in the synovial fluid that the same peptide epitope can induce an immune response in different diseases may have important practical lymphocytes of patients with juvenile RA and GRP peptide specific CD4 ϩ T cell clones have been obtained from the implications. The identification of widespread peptide antigens may suggest their potential utilization in the suppression synovial fluid of these patients (19). Interestingly the GRP immune response. In the past few years several groups have
